Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach
A Phase I/II Trial of the c-Met Inhibitor, Tivantinib, in Combination With FOLFOX for the Treatment of Patients With Advanced Solid Tumors (Phase I) and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal (GE) Junction, or Stomach (Phase II)
Status: Enrolling
Updated:  1/15/2016
Florida Cancer Specialists-Sarasota
mi
from
Sarasota, FL
Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach
A Phase I/II Trial of the c-Met Inhibitor, Tivantinib, in Combination With FOLFOX for the Treatment of Patients With Advanced Solid Tumors (Phase I) and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal (GE) Junction, or Stomach (Phase II)
Status: Enrolling
Updated: 1/15/2016
Florida Cancer Specialists-Sarasota
mi
from
Sarasota, FL
Click here to add this to my saved trials
Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach
A Phase I/II Trial of the c-Met Inhibitor, Tivantinib, in Combination With FOLFOX for the Treatment of Patients With Advanced Solid Tumors (Phase I) and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal (GE) Junction, or Stomach (Phase II)
Status: Enrolling
Updated:  1/15/2016
Florida Cancer Specialists-North
mi
from
St. Petersburg, FL
Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach
A Phase I/II Trial of the c-Met Inhibitor, Tivantinib, in Combination With FOLFOX for the Treatment of Patients With Advanced Solid Tumors (Phase I) and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal (GE) Junction, or Stomach (Phase II)
Status: Enrolling
Updated: 1/15/2016
Florida Cancer Specialists-North
mi
from
St. Petersburg, FL
Click here to add this to my saved trials
Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach
A Phase I/II Trial of the c-Met Inhibitor, Tivantinib, in Combination With FOLFOX for the Treatment of Patients With Advanced Solid Tumors (Phase I) and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal (GE) Junction, or Stomach (Phase II)
Status: Enrolling
Updated:  1/15/2016
Oklahoma University
mi
from
Oklahoma City, OK
Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach
A Phase I/II Trial of the c-Met Inhibitor, Tivantinib, in Combination With FOLFOX for the Treatment of Patients With Advanced Solid Tumors (Phase I) and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal (GE) Junction, or Stomach (Phase II)
Status: Enrolling
Updated: 1/15/2016
Oklahoma University
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach
A Phase I/II Trial of the c-Met Inhibitor, Tivantinib, in Combination With FOLFOX for the Treatment of Patients With Advanced Solid Tumors (Phase I) and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal (GE) Junction, or Stomach (Phase II)
Status: Enrolling
Updated:  1/15/2016
South Carolina Oncology Associates, PA
mi
from
Columbia, SC
Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach
A Phase I/II Trial of the c-Met Inhibitor, Tivantinib, in Combination With FOLFOX for the Treatment of Patients With Advanced Solid Tumors (Phase I) and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal (GE) Junction, or Stomach (Phase II)
Status: Enrolling
Updated: 1/15/2016
South Carolina Oncology Associates, PA
mi
from
Columbia, SC
Click here to add this to my saved trials
Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach
A Phase I/II Trial of the c-Met Inhibitor, Tivantinib, in Combination With FOLFOX for the Treatment of Patients With Advanced Solid Tumors (Phase I) and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal (GE) Junction, or Stomach (Phase II)
Status: Enrolling
Updated:  1/15/2016
Tennessee Oncology-Chattanooga
mi
from
Chattanooga, TN
Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach
A Phase I/II Trial of the c-Met Inhibitor, Tivantinib, in Combination With FOLFOX for the Treatment of Patients With Advanced Solid Tumors (Phase I) and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal (GE) Junction, or Stomach (Phase II)
Status: Enrolling
Updated: 1/15/2016
Tennessee Oncology-Chattanooga
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach
A Phase I/II Trial of the c-Met Inhibitor, Tivantinib, in Combination With FOLFOX for the Treatment of Patients With Advanced Solid Tumors (Phase I) and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal (GE) Junction, or Stomach (Phase II)
Status: Enrolling
Updated:  1/15/2016
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach
A Phase I/II Trial of the c-Met Inhibitor, Tivantinib, in Combination With FOLFOX for the Treatment of Patients With Advanced Solid Tumors (Phase I) and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal (GE) Junction, or Stomach (Phase II)
Status: Enrolling
Updated: 1/15/2016
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Click here to add this to my saved trials
Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach
A Phase I/II Trial of the c-Met Inhibitor, Tivantinib, in Combination With FOLFOX for the Treatment of Patients With Advanced Solid Tumors (Phase I) and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal (GE) Junction, or Stomach (Phase II)
Status: Enrolling
Updated:  1/15/2016
The Center for Cancer and Blood Disorders
mi
from
Fort Worth, TX
Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach
A Phase I/II Trial of the c-Met Inhibitor, Tivantinib, in Combination With FOLFOX for the Treatment of Patients With Advanced Solid Tumors (Phase I) and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal (GE) Junction, or Stomach (Phase II)
Status: Enrolling
Updated: 1/15/2016
The Center for Cancer and Blood Disorders
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Group-Based Lifestyle Intervention in Measuring Biomarker Levels in Participants at High Risk for Breast Cancer
Diet, Exercise and Estrogen Metabolites Study (DEEM)
Status: Enrolling
Updated:  1/15/2016
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Group-Based Lifestyle Intervention in Measuring Biomarker Levels in Participants at High Risk for Breast Cancer
Diet, Exercise and Estrogen Metabolites Study (DEEM)
Status: Enrolling
Updated: 1/15/2016
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Bile Duct, Gallbladder, or Pancreatic Cancer
Phase I Dose Escalation and Pharmacokinetics Study of the Radiosensitizer, Gadolinium Texaphyrin (Gd-Tex, NSC 695238) With Concurrent Radiotherapy in Advanced Biliary Tree and Pancreatic Cancers
Status: Enrolling
Updated:  1/15/2016
Norris Cotton Cancer Center
mi
from
Lebanon, NH
Radiation Therapy in Treating Patients With Bile Duct, Gallbladder, or Pancreatic Cancer
Phase I Dose Escalation and Pharmacokinetics Study of the Radiosensitizer, Gadolinium Texaphyrin (Gd-Tex, NSC 695238) With Concurrent Radiotherapy in Advanced Biliary Tree and Pancreatic Cancers
Status: Enrolling
Updated: 1/15/2016
Norris Cotton Cancer Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Bile Duct, Gallbladder, or Pancreatic Cancer
Phase I Dose Escalation and Pharmacokinetics Study of the Radiosensitizer, Gadolinium Texaphyrin (Gd-Tex, NSC 695238) With Concurrent Radiotherapy in Advanced Biliary Tree and Pancreatic Cancers
Status: Enrolling
Updated:  1/15/2016
University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Radiation Therapy in Treating Patients With Bile Duct, Gallbladder, or Pancreatic Cancer
Phase I Dose Escalation and Pharmacokinetics Study of the Radiosensitizer, Gadolinium Texaphyrin (Gd-Tex, NSC 695238) With Concurrent Radiotherapy in Advanced Biliary Tree and Pancreatic Cancers
Status: Enrolling
Updated: 1/15/2016
University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Bile Duct, Gallbladder, or Pancreatic Cancer
Phase I Dose Escalation and Pharmacokinetics Study of the Radiosensitizer, Gadolinium Texaphyrin (Gd-Tex, NSC 695238) With Concurrent Radiotherapy in Advanced Biliary Tree and Pancreatic Cancers
Status: Enrolling
Updated:  1/15/2016
University of Wisconsin Comprehensive Cancer Center
mi
from
Madison, WI
Radiation Therapy in Treating Patients With Bile Duct, Gallbladder, or Pancreatic Cancer
Phase I Dose Escalation and Pharmacokinetics Study of the Radiosensitizer, Gadolinium Texaphyrin (Gd-Tex, NSC 695238) With Concurrent Radiotherapy in Advanced Biliary Tree and Pancreatic Cancers
Status: Enrolling
Updated: 1/15/2016
University of Wisconsin Comprehensive Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
Hepatic Arterial Chemoembolization With Cisplatin or Internal Radiation Therapy in Treating Patients With Advanced Liver Cancer That Cannot Be Removed By Surgery
A Prospectively Randomized Controlled Clinical Trial Comparing TheraSphere With Cisplatin-Based TACE (Trans Arterial Chemo Embolization) in the Management of Advanced Stage, Unresectable Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  1/15/2016
Hillman Cancer Center at University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Hepatic Arterial Chemoembolization With Cisplatin or Internal Radiation Therapy in Treating Patients With Advanced Liver Cancer That Cannot Be Removed By Surgery
A Prospectively Randomized Controlled Clinical Trial Comparing TheraSphere With Cisplatin-Based TACE (Trans Arterial Chemo Embolization) in the Management of Advanced Stage, Unresectable Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 1/15/2016
Hillman Cancer Center at University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Hot Springs, AR
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Hot Springs, AR
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Jonesboro, AR
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Jonesboro, AR
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Greenbrae, CA
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Greenbrae, CA
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Colorado Springs, CO
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Bonita Springs, FL
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Bonita Springs, FL
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Bradenton, FL
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Bradenton, FL
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Cape Coral, FL
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Cape Coral, FL
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
mi
from
Ft. Meyers, FL
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
mi
from
Ft. Meyers, FL
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Naples, FL
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Naples, FL
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Port Charlotte, FL
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Port Charlotte, FL
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Sarasota, FL
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Sarasota, FL
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Venice, FL
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Venice, FL
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Atlanta, GA
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Augusta, GA
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Augusta, GA
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Macon, GA
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Macon, GA
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Marietta, GA
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Marietta, GA
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Chicago, IL
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Minneapolis, MN
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Billings, MT
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Billings, MT
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Albany, NY
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Albany, NY
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
East Setauket, NY
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
East Setauket, NY
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Kettering, OH
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Kettering, OH
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Greenville, SC
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Greenville, SC
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Nashville, TN
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Dallas, TX
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Ft. Worth, TX
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Ft. Worth, TX
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Tyler, TX
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Tyler, TX
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Spokane, WA
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Spokane, WA
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Marshfield, WI
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Marshfield, WI
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
mi
from
Belo Horizonte,
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
mi
from
Belo Horizonte,
Click here to add this to my saved trials
Study of Gefitinib and Docetaxel as Salvage Therapy in Advanced Pancreatic Carcinoma
Phase II Study of Gefitinib and Docetaxel as Salvage Therapy in Advanced Pancreatic Carcinoma
Status: Enrolling
Updated:  1/15/2016
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Study of Gefitinib and Docetaxel as Salvage Therapy in Advanced Pancreatic Carcinoma
Phase II Study of Gefitinib and Docetaxel as Salvage Therapy in Advanced Pancreatic Carcinoma
Status: Enrolling
Updated: 1/15/2016
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Study of Pemetrexed and Bevacizumab in Patients With Head and Neck Cancer
Phase II Trial of Pemetrexed and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer
Status: Enrolling
Updated:  1/15/2016
Hillman Cancer Center
mi
from
Pittsburgh, PA
Study of Pemetrexed and Bevacizumab in Patients With Head and Neck Cancer
Phase II Trial of Pemetrexed and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer
Status: Enrolling
Updated: 1/15/2016
Hillman Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases
A Phase III Trial to Test the Efficacy of ZD4054(Zibotentan), an Endothelin A Receptor Antagonist, Versus Placebo in Patients With Hormone Resistant Prostate Cancer (HRPC) and Bone Metastasis Who Are Pain Free and Mildly Symptomatic.
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Tucson, AZ
A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases
A Phase III Trial to Test the Efficacy of ZD4054(Zibotentan), an Endothelin A Receptor Antagonist, Versus Placebo in Patients With Hormone Resistant Prostate Cancer (HRPC) and Bone Metastasis Who Are Pain Free and Mildly Symptomatic.
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases
A Phase III Trial to Test the Efficacy of ZD4054(Zibotentan), an Endothelin A Receptor Antagonist, Versus Placebo in Patients With Hormone Resistant Prostate Cancer (HRPC) and Bone Metastasis Who Are Pain Free and Mildly Symptomatic.
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Greenbrae, CA
A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases
A Phase III Trial to Test the Efficacy of ZD4054(Zibotentan), an Endothelin A Receptor Antagonist, Versus Placebo in Patients With Hormone Resistant Prostate Cancer (HRPC) and Bone Metastasis Who Are Pain Free and Mildly Symptomatic.
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Greenbrae, CA
Click here to add this to my saved trials
A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases
A Phase III Trial to Test the Efficacy of ZD4054(Zibotentan), an Endothelin A Receptor Antagonist, Versus Placebo in Patients With Hormone Resistant Prostate Cancer (HRPC) and Bone Metastasis Who Are Pain Free and Mildly Symptomatic.
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Los Angeles, CA
A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases
A Phase III Trial to Test the Efficacy of ZD4054(Zibotentan), an Endothelin A Receptor Antagonist, Versus Placebo in Patients With Hormone Resistant Prostate Cancer (HRPC) and Bone Metastasis Who Are Pain Free and Mildly Symptomatic.
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases
A Phase III Trial to Test the Efficacy of ZD4054(Zibotentan), an Endothelin A Receptor Antagonist, Versus Placebo in Patients With Hormone Resistant Prostate Cancer (HRPC) and Bone Metastasis Who Are Pain Free and Mildly Symptomatic.
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Palm Springs, CA
A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases
A Phase III Trial to Test the Efficacy of ZD4054(Zibotentan), an Endothelin A Receptor Antagonist, Versus Placebo in Patients With Hormone Resistant Prostate Cancer (HRPC) and Bone Metastasis Who Are Pain Free and Mildly Symptomatic.
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Palm Springs, CA
Click here to add this to my saved trials
A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases
A Phase III Trial to Test the Efficacy of ZD4054(Zibotentan), an Endothelin A Receptor Antagonist, Versus Placebo in Patients With Hormone Resistant Prostate Cancer (HRPC) and Bone Metastasis Who Are Pain Free and Mildly Symptomatic.
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
San Mateo, CA
A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases
A Phase III Trial to Test the Efficacy of ZD4054(Zibotentan), an Endothelin A Receptor Antagonist, Versus Placebo in Patients With Hormone Resistant Prostate Cancer (HRPC) and Bone Metastasis Who Are Pain Free and Mildly Symptomatic.
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
San Mateo, CA
Click here to add this to my saved trials
A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases
A Phase III Trial to Test the Efficacy of ZD4054(Zibotentan), an Endothelin A Receptor Antagonist, Versus Placebo in Patients With Hormone Resistant Prostate Cancer (HRPC) and Bone Metastasis Who Are Pain Free and Mildly Symptomatic.
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
mi
from
Norwich, CT
A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases
A Phase III Trial to Test the Efficacy of ZD4054(Zibotentan), an Endothelin A Receptor Antagonist, Versus Placebo in Patients With Hormone Resistant Prostate Cancer (HRPC) and Bone Metastasis Who Are Pain Free and Mildly Symptomatic.
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
mi
from
Norwich, CT
Click here to add this to my saved trials